Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

BACKGROUND: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responde...

Descripción completa

Detalles Bibliográficos
Autores principales: Pradier, Melanie F., Reis, Bernhard, Jukofsky, Lori, Milletti, Francesca, Ohtomo, Toshihiko, Perez-Cruz, Fernando, Puig, Oscar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438135/
https://www.ncbi.nlm.nih.gov/pubmed/30922327
http://dx.doi.org/10.1186/s12885-019-5472-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438135/
https://www.ncbi.nlm.nih.gov/pubmed/30922327
http://dx.doi.org/10.1186/s12885-019-5472-0

Ejemplares similares